0.00Open0.00Pre Close0 Volume0 Open Interest50.00Strike Price0.00Turnover732.26%IV-1523.38%PremiumJan 17, 2025Expiry Date46.92Intrinsic Value100Multiplier22DDays to Expiry0.00Extrinsic Value100Contract SizeAmericanOptions Type-0.7415Delta0.0624Gamma0.07Leverage Ratio-0.0372Theta-0.0145Rho-0.05Eff Leverage0.0025Vega
Revance Therapeutics Stock Discussion
Crown Laboratories and Revance Enter into Amended and Restated Merger Agreement
Crown Laboratories and Revance Therapeutics (NASDAQ: RVNC) have announced an amended merger agreement where Crown will acquire all outstanding Revance shares for $3.10 per share in cash through a tender offer. The amendment comes after several developments, including Revance's settlement with Teoxane regarding distribution agreements and revised brand guidelines, which are expect...
📊⚡️📊
No comment yet